A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine (CHALLENGE-MIG)
I5Q-MC-CGBD - ClinicalTrials.gov - NCT05127486
The purpose of this study is to assess whether galcanezumab is superior to rimegepant in the prevention of migraine in participants with episodic migraine.
Trial Summary
Age Range
18 - 75 yearsConditions the trial is for
Headache DisordersWhat the trial is testing?
galcanezumab (LY2951742)Could I receive a Placebo?
YesEnrollment Goal
580Trial Dates
Dec 6, 2021 - May 23, 2023How long will I be in the trial?
Your participation could last about 6 months and may include up to 6 visits to the study center.Trial Phase
IVKey Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participants must have migraines with or without aura
Participants Must Not:
Participants must not be allergic to certain types of drugs
Participants must not have had a heart attack or stroke in the last 6 months
Participants must not be pregnant or nursing
Participants must not have serious mood or anxiety disorders
Lilly Trial Alerts
Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo